Heat Biologics Inc (HTBX) - Financial and Strategic SWOT Analysis Review

April 2021 | 47 pages | ID: HB3DB2181B37EN
GlobalData

Abstracts

Heat Biologics Inc (HTBX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Heat Biologics Inc (Heat Biologics) is a biopharmaceutical company which develops novel immuno therapeutics for the treatment of cancer. Its pipeline encompasses viagenpumatucel-L based investigational candidate targeted at the treatment of non-small cell lung cancer, and co-stimulatory antibodies targeted at tumors. The co-stimulatory antibodies harness human body's natural antigen specific immune response to reprogram the immune system to offer durable clinical outcomes. Heat Biologics’ off-the-shelf therapies are based on its proprietary T-cell activating platform (TCAP), which turns immunologically cold tumors hot. It operates through subsidiaries in the US, Germany and Australia. Heat Biologics is headquartered in Durham, North Carolina, the US.

Heat Biologics Inc Key Recent Developments

Mar 25,2021: Heat Biologics provides year - end business update
Feb 12,2021: Heat Biologics to Present at 2021 BIO CEO & Investor Digital Conference
Jan 11,2021: Heat Biologics promotes William L. Ostrander to chief financial officer
Dec 10,2020: Heat Biologics provides business update
Nov 09,2020: Heat Biologics provides third quarter 2020 business update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Heat Biologics Inc - Key Facts
Heat Biologics Inc - Key Employees
Heat Biologics Inc - Key Employee Biographies
Heat Biologics Inc - Major Products and Services
Heat Biologics Inc - History
Heat Biologics Inc - Company Statement
Heat Biologics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Heat Biologics Inc - Business Description
R&D Overview
Heat Biologics Inc - Corporate Strategy
Heat Biologics Inc - SWOT Analysis
SWOT Analysis - Overview
Heat Biologics Inc - Strengths
Heat Biologics Inc - Weaknesses
Heat Biologics Inc - Opportunities
Heat Biologics Inc - Threats
Heat Biologics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Heat Biologics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 25, 2021: Heat Biologics provides year - end business update
Feb 12, 2021: Heat Biologics to Present at 2021 BIO CEO & Investor Digital Conference
Jan 11, 2021: Heat Biologics promotes William L. Ostrander to chief financial officer
Dec 10, 2020: Heat Biologics provides business update
Nov 09, 2020: Heat Biologics provides third quarter 2020 business update
Aug 07, 2020: Heat Biologics provides second quarter 2020 business update
Jun 04, 2020: Heat Biologics provides update on COVID-19 vaccine efforts
May 15, 2020: Heat Biologics provides first quarter 2020 business update
Apr 01, 2020: Heat Biologics announces formation of COVID-19 Advisory Board
Mar 30, 2020: Heat Biologics provides year-end business update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Heat Biologics Inc, Key Facts
Heat Biologics Inc, Key Employees
Heat Biologics Inc, Key Employee Biographies
Heat Biologics Inc, Major Products and Services
Heat Biologics Inc, History
Heat Biologics Inc, Subsidiaries
Heat Biologics Inc, Key Competitors
Heat Biologics Inc, Ratios based on current share price
Heat Biologics Inc, Annual Ratios
Heat Biologics Inc, Annual Ratios (Cont...1)
Heat Biologics Inc, Interim Ratios
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Heat Biologics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Heat Biologics Inc, Performance Chart (2016 - 2020)
Heat Biologics Inc, Ratio Charts
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021